Chromosome damage and second malignancy in patients treated with melphalan

Area of Science:

• Cytogenetics
• Cancer Therapy
• Molecular Biology

Background:

• Melphalan is a chemotherapeutic agent used in cancer treatment.
• Understanding the long-term genotoxic effects of melphalan is crucial for patient monitoring.

Purpose of the Study:

• To investigate the persistence of melphalan-induced cytogenetic damage in cancer patients.
• To evaluate the utility of sister chromatid exchange (SCE) and chromosomal aberrations as biomarkers for melphalan exposure.

Main Methods:

• Peripheral lymphocytes from cancer patients were analyzed for sister chromatid exchange (SCE) and chromosomal aberrations at various times post-melphalan therapy.
• In-vitro studies assessed SCE induction and repair in different lymphocyte cell cycle phases (G0 and G1).

Main Results:

• SCE frequency increased shortly after melphalan treatment but returned to baseline within four weeks.
• Chromosomal aberrations, including translocations and complex rearrangements, were elevated for up to ten years post-therapy.
• Specific chromosomes (8 and 9) showed overrepresentation in aberrant cells, and persistent rearrangements were observed in T-lymphocytes.

Conclusions:

• While SCE is a sensitive marker for acute melphalan-induced damage, chromosomal aberrations are better indicators of long-term genetic alterations.
• Persistent chromosomal damage after melphalan therapy may be compatible with cell survival and proliferation.
• The study highlights the need for long-term cytogenetic surveillance in patients treated with melphalan.